Abstract Library

#1755 Immune-Related Factors Analysis Enhances the Stratification of GEP-NENs Patients Into Distinct Prognostic Subsets

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are divided into different prognostic categories according to Ki67 class (≤2%: 2%-20%; 20%-55%; >55%); treatment strategies based on this classification are not fully effective.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Milione M

Authors: Milione M, Miceli R, Pellegrinelli A, Centonze G, Barretta F,

Keywords: Ki67, immune-related markers, disease-free survival, PD-L1,

#1748 External Validation of Prognostic Classification Score for Predicting Overall Survival (OS) of Patients (pts) with Advanced Well Differentiated Neuroendocrine Tumour (WDNET). Neuroendocrine European Prognostic Score (NEP Score Working Group)

Introduction: Absence of relevant prognostic score (PS) in NET

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pusceddu S

Authors: Pusceddu S, Barretta F, Botta L, Trama A, Milione M,

Keywords: neuroendocrine, prognostic score,

#152 Validation of a new assay that uses 2 monoclonal antibodies to measure intact and fragmented plasma CgA levels

Introduction: Plasma chromogranin A (CgA) levels are elevated in a variety of neuroendocrine tumors (NETs) and are used to aid in diagnosis, prognosis, and monitoring of treatment effects in NETs patients. We evaluated a newer sandwich ELISA assay (Cisbio US, Bedford, MA, USA) that utilizes two monoclonal antibodies that bind to the mid-region of the CgA protein and allow measurement of intact and fragmented circulating CgA. The results from the assay validation indicative of its overall robustness in terms of sensitivity, specificity, reproducibility, and stability are presented here.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Motwani M, Nuti S, Tsuchihashi Z, Barrett J,

Keywords: chromogranin A, CgA, neuroendocrine tumor, pancreatic NETs, ELISA, biomarker,